SEC Form D filing

Ancilia Biosciences, Inc., 2026-04-06

An SEC Form D private-offering notice from New York, NY, a $10,076,464 filer-stated offering target in Biotech. Filed 2026-04-06. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Ancilia Biosciences, Inc. site↗ Verified via SEC Form D

Develops CRISPR based bacterial therapeutics and live biotherapeutics with resistance to viral bacteriophages, initially targeting vaginal microbiome health.

Filed 2026-04-06Filed to raise $10,076,464First money in 2026-02-13Raised so far $10,076,464HQ (as filed) New York, NYSector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status Delayed filing
Source linked the Form D on EDGAR↗Website verified anciliabio.com↗Named in the filing 5 executives & directors
Open this row on the live feed →More new filings in New York →More Biotech filings →

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source